With the advances in technology we have studied in this course, there seems to be a significant opportunity for IT to impact the costs of delivering healthcare. There are many challenges
https://evisit.com/what-is-telemedicine/ (Links to an external site.)Links to an external site.
The above link will provide you with a good definition and background on telehealth and telemedicine.
https://www.partners.org/for-patients/Partners-Patient-Gateway.aspx (Links to an external site.)Links to an external site.
This link is a pointer to an example of a patient-provider health information system. You will not be able to login unless you are a patient. Browse and see some of the features.
With the advances in technology we have studied in this course, there seems to be a significant opportunity for IT to impact the costs of delivering healthcare. There are many challenges to making quality healthcare available across the country whether in urban or rural areas. As an example, the need to transport patients from nursing homes and assisted living to hospitals or even doctor’s offices to be “evaluated and treated” would seem to be an opportunity for telemedicine to address.
ASSIGNMENT – In a 4 page paper, discuss what you see as the opportunity and challenges of expanding telehealth. Remember to discuss the opportunity (challenges, competition, demand, etc.), the challenges (privacy, security, etc), and what you think the IT environment would be like and who would manage it.
Order This Solution
49051 Millions developed by 10% and working benefit in 2009 was 15012 Millions that developed by 6%. Roche is contributed CHF. 9874 Millions on R&D in 2009. The free trade stream out 2009 was 8893 that was 79% more than 2008. The aggregate representative of Roche are 81507. Out of them 80115 are changeless. The Sales commitment is more from US that is 38% than West Europe that is 28%. Since pharmaceutical advertising exercises impact the endorsing conduct of specialists, it is of most extreme significance to basically dissect the cases made in the limited time material of the medications. The degree to which pharmaceutical organizations advance the benefits of their items and applicable clinical trails give to specialists are not examined in Pakistan. The consequences of the present logical examination demonstrate that untrustworthy and one-sided claims with respect to the pharmaceutical items are uncontrolled in Pakistan. These medication advancements impact the recommending conduct of the General Practitioners, Consultants in this manner representing one of the possibly significant reasons for outlandish solution. Roche Pakistan Ltd is a Member of IFPMA and PMA and take after their moral business rules to offer its items. Roche Paksitan Ltd is at sixth positioning in Pakistan Pharmaceutical Market and its yearly deal is Rs. 5.2 Billions out of 2009 in Pakistan.>GET ANSWER